Clinical Trials
40
Active:6
Completed:16
Trial Phases
4 Phases
Phase 1:20
Phase 2:11
Phase 3:8
+1 more phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (40 trials with phase data)• Click on a phase to view related trials
Phase 1
20 (50.0%)Phase 2
11 (27.5%)Phase 3
8 (20.0%)Not Applicable
1 (2.5%)Efficacy and Safety of HRS9531 in Participants With Type 2 Diabetes Treated With Basal Insulin
Not Applicable
Not yet recruiting
- Conditions
- Type 2 Diabetes
- Interventions
- Drug: HRS953Drug: Placebo
- First Posted Date
- 2025-07-11
- Last Posted Date
- 2025-07-11
- Lead Sponsor
- Fujian Shengdi Pharmaceutical Co., Ltd.
- Target Recruit Count
- 300
- Registration Number
- NCT07060456
- Locations
- 🇨🇳
Perking University Peoples' Hospital, Beijing, Beijing, China
A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study to Evaluate the Efficacy and Safety of HRS9531 Injection in Subjects With Obstructive Sleep Apnea (OSA) and Obesity Who Are on Positive Airway Pressure Ventilation (PAP) Therapy
Phase 3
Not yet recruiting
- Conditions
- Subjects With Moderate-to-severe OSA and Obesity Who Are on PAP Therapy
- Interventions
- Drug: Placebo
- First Posted Date
- 2025-05-29
- Last Posted Date
- 2025-05-29
- Lead Sponsor
- Fujian Shengdi Pharmaceutical Co., Ltd.
- Target Recruit Count
- 140
- Registration Number
- NCT06994650
- Locations
- 🇨🇳
Peking University People's Hospital, Beijing, Beijing, China
A Phase III Study Evaluating the Efficacy and Safety of HRS9531 Injection in Subjects With Obstructive Sleep Apnea (OSA) and Obesity
Phase 3
Not yet recruiting
- Conditions
- Bstructive Sleep Apnea (OSA) and Obesity
- Interventions
- Drug: HRS9531placebo
- First Posted Date
- 2025-05-16
- Last Posted Date
- 2025-05-16
- Lead Sponsor
- Fujian Shengdi Pharmaceutical Co., Ltd.
- Target Recruit Count
- 140
- Registration Number
- NCT06974851
- Locations
- 🇨🇳
Beijing Hospital, Beijing, Beijing, China
A Phase Ⅰ Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HRS-5817 Injection
Phase 1
Not yet recruiting
- Conditions
- ObesityOverweight
- Interventions
- Drug: HRS-5817 InjectionDrug: HRS-5817 Injection Placebo
- First Posted Date
- 2025-04-18
- Last Posted Date
- 2025-04-18
- Lead Sponsor
- Fujian Shengdi Pharmaceutical Co., Ltd.
- Target Recruit Count
- 44
- Registration Number
- NCT06934408
- Locations
- 🇨🇳
The Second Hospital of Anhui Medical Uniersity, Hefei, Anhui, China
Mass Balance Study of [14C]HRS9531 in Healthy Male Subjects
Phase 1
Completed
- Conditions
- Type 2 Diabetes MellitusWeight Loss
- Interventions
- Drug: [14C]HRS9531
- First Posted Date
- 2025-03-03
- Last Posted Date
- 2025-07-04
- Lead Sponsor
- Fujian Shengdi Pharmaceutical Co., Ltd.
- Target Recruit Count
- 7
- Registration Number
- NCT06855147
- Locations
- 🇨🇳
The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China
- Prev
- 1
- 2
- 3
- 4
- 5
- 8
- Next
News
No news found